Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, comments on the possibility of introducing BCMA-targeted regimens earlier in the treatment of patients with multiple myeloma. Dr Popat explains that data has shown that treatments are more effective in earlier lines of therapy (LOT) and clinical trials including KarMMa-3 (NCT03651128) and CARTITUDE-4 (NCT04181827) have shown the efficacy and improved tolerability of CAR-T therapy in earlier LOT. Dr Popat also comments on treatment sequencing, explaining the mechanisms of resistance to T-cell engagers and antibody-drug conjugates. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
